Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Evercore ISI Group Downgrades Douglas Emmett to In-Line, Lowers Price Target to $24

Evercore ISI Group analyst Steve Sakwa downgrades Douglas Emmett (NYSE:DEI) from Outperform to In-Line and lowers the price target from $27 to $24.
byBenzinga Newsdesk
September 27, 2022
1 minute read
Total
0
Shares
0
0
0
0
0
0

Evercore ISI Group analyst Steve Sakwa downgrades Douglas Emmett (NYSE:DEI) from Outperform to In-Line and lowers the price target from $27 to $24.

 
Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Share 0
Related Posts
Read More

EyePoint Pharmaceuticals Announces Two Presentations Of Topline Data With Additional Subgroup Analyses From The Phase 2 DAVIO 2 Clinical Trial Of EYP-1901 For The Treatment Of Wet Age-Related Macular Degeneration

By Benzinga Newsdesk
February 4, 2:37 PM
Subgroup analyses underscore favorable clinical profile and durability of EYP-1901Presentations highlight previously reported positive Phase 2 DAVIO 2 topline results showing all primary and secondary endpoints were

EYPT